Global Microbiome Partnering Terms and Agreements 2010 to 2022

Global Microbiome Partnering Terms and Agreements 2010 to 2022

The Global Microbiome Partnering Terms and Agreements 2010 to 2022 report provides an understanding and access to the microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in microbiome partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Microbiome partnering contract documents
Top microbiome deals by value

The Global Microbiome Partnering Terms and Agreements report provides an understanding and access to the microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in microbiome dealmaking with a brief summary followed by a comprehensive listing of microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by microbiome partnering company A-Z, deal type definitions and microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in microbiome partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of microbiome technologies and products.

Report scope

Global Microbiome Partnering Terms and Agreements 2010 to 2022 is intended to provide the reader with an in-depth understanding and access to microbiome trends and structure of deals entered into by leading companies worldwide.

Global Microbiome Partnering Terms and Agreements 2010 to 2022 includes:

Trends in microbiome dealmaking in the biopharma industry since 2010
Access to headline, upfront, milestone and royalty data
Access to over 250 microbiome deal records and contract documents where available
The leading microbiome deals by value since 2010
Most active microbiome dealmakers since 2010
The leading microbiome partnering resources

In Global Microbiome Partnering Terms and Agreements 2010 to 2022, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


  • Executive Summary
  • Introduction
  • Trends in microbiome dealmaking
    • Introduction
    • Microbiome partnering over the years
    • Most active microbiome dealmakers
    • Microbiome partnering by deal type
    • Microbiome partnering by therapy area
    • Deal terms for microbiome partnering
      • Microbiome partnering headline values
        • Table Microbiome deals with a headline value
      • Microbiome deal upfront payments
        • Table Microbiome deals with an upfront value
      • Microbiome deal milestone payments
        • Table Microbiome deals with a milestone value
      • Microbiome royalty rates
        • Table Microbiome deals with a royalty rate value
  • Leading microbiome deals
    • Introduction
    • Top microbiome deals by value
      • Table Top microbiome deals by value since 2010
  • Most active microbiome dealmakers
    • Introduction
    • Most active microbiome dealmakers
    • Most active microbiome partnering company profiles
      • Second Genome
      • Enterome Bioscience
      • Seres Therapeutics
      • OptiBiotix
      • Vedanta Biosciences
      • Ferring Pharmaceuticals
      • Bio-Me
      • Diversigen
      • Janssen Research & Development
      • Kaleido Biosciences
      • Mayo Clinic
      • MyBiotics Pharma
      • Bristol-Myers Squibb
      • Eagle Genomics
      • Eligo Bioscience
      • Evolve BioSystems
      • Genetic Analysis
      • Johnson & Johnson Consumer Companies
      • Johnson & Johnson Innovation
      • Metabiomics
      • National Institutes of Health
      • Rebiotix
      • Synthetic Biologics
      • Zymo Research
      • Azitra
  • Microbiome contracts dealmaking directory
    • Introduction
    • Microbiome contracts dealmaking directory
  • Microbiome dealmaking by technology type
    • Microbiome
  • Appendices
    • Microbiome deals by company A-Z
      • 4D Pharma
      • 9 Meters Biopharma
      • Aarhus University
      • Abbott Laboratories
      • Abbvie
      • ADL Bionatur Solutions
      • ADM
      • AIDS Clinical Trials Group
      • Alimentary Health
      • Allergan
      • ALS Association
      • Amag Pharmaceuticals
      • American Type Culture Collection (ATCC)
      • Ancilia Biosciences
      • AnimalBiome
      • AntibioTx
      • Archer Daniels Midland Company
      • Arc Bio
      • Arena Pharmaceuticals
      • Argonne National Laboratory
      • Ariana Pharma
      • Arranta Bio
      • Artizan Biosciences
      • Assembly Biosciences
      • AstraZeneca
      • Ateria Health
      • Aurealis Therapeutics
      • Azitra
      • BASF
      • Bayer
      • Bayer CropScience
      • Bayer Healthcare
      • Baylor College of Medicine
      • Baylor Miraca Genetics Laboratories
      • Beam Therapeutics
      • Bertin Pharma
      • Bill and Melinda Gates Foundation
      • Bio-Me
      • Bio-Rad Laboratories
      • BIOASTER
      • Biocodex Microbiota Foundation
      • Biocogent
      • Biocore
      • Biofortis
      • Biohaven Pharmaceuticals
      • BiomeBank
      • Biomecite Diagnostics
      • Biomedical Advanced Research and Development Authority
      • Biomica
      • Biomillenia
      • Biomodels
      • BiomX
      • BionX Medical Technologies
      • Biosortia Pharmaceuticals
      • Bio Palette
      • Bloom Science
      • Boehringer Ingelheim
      • Boston University School of Medicine
      • Brigham and Women's Hospital
      • Bristol-Myers Squibb
      • Brown University
      • Cancer Research UK
      • CARB-X
      • Carbiotix
      • Cargill
      • Cedars-Sinai Medical Center
      • Centers for Disease Control and Prevention
      • Centre Leon Berard
      • Centre National de la Recherche Scientifique
      • Centro Sperimentale del Latte
      • Children's Hospital Boston
      • Circuit Clinical
      • Clalit Health Services
      • CN Bio
      • Commense
      • Companion PBx
      • Compass Minerals Plant Nutrition
      • ConsortiaTX
      • COPD Foundation
      • CoreBiome
      • Cornell University
      • CosmosID
      • Crohn's and Colitis Foundation of America
      • CryoXtract
      • Dana-Farber Cancer Institute
      • DayTwo
      • DDL Diagnostic Laboratory
      • Debiopharm
      • Defense Advanced Research Projects Agency
      • Department of Health and Human Services
      • Dermala
      • Diversigen
      • DuPont
      • DuPont Pharmaceuticals
      • DuPont Pioneer
      • Eagle Genomics
      • EcoMetrix
      • Elanco
      • Eligo Bioscience
      • Emulate
      • EnBiotix
      • Enterome Bioscience
      • EpiBiome
      • European Commission
      • Evah
      • Evelo Biosciences
      • Evogene
      • Evolve BioSystems
      • Evotec
      • ExeGi Pharma
      • Felix Biotechnology
      • Ferring Pharmaceuticals
      • Finch Therapeutics
      • Florida International University
      • Food Marble Digestive Health
      • Forsyth Institute
      • French National Institute for Agricultural Research
      • Fundacion Progreso y Salud
      • Galmed Pharmaceuticals
      • Genentech
      • General Automation Lab Technologies
      • Genetic Analysis
      • Genewiz
      • GenomeQuest
      • Genome and Company
      • Georges Francois Leclerc Center
      • German Cryo
      • Gilead Sciences
      • Ginkgo BioWorks
      • GlaxoSmithKline
      • Glycosyn
      • Gnubiotics Sciences
      • Greenteaspoon
      • Hackensack Meridian Health
      • Hadassah Medical Center
      • Hamilton Company
      • Harvard School of Public Health
      • Harvard University
      • Health Canada
      • Helomics
      • HLH BioPharma Vertriebs
      • Holobiome
      • Horizon Europe
      • Hospital of University of Strasbourg
      • Hudson Institute of Medical Research
      • Human Longevity
      • Hy Laboratories
      • IBM
      • Illumina
      • Immuron
      • Innovate Biopharmaceuticals
      • Inserm
      • Inspirotec
      • Institute For Life Science Entrepreneurship (ILSE)
      • Institut De Recherche Pour Le Developpement (IRD)
      • Institut Gustave Roussy
      • Institut National Recherche Agronomique
      • International Centre for Diarrhoeal Disease Research
      • Intract Pharma
      • Intralytix
      • Ipsen
      • ISOThrive
      • Jackson Laboratory
      • Janssen Biotech
      • Janssen Human Microbiome Institute
      • Janssen Research & Development
      • Janssen Therapeutics
      • Jennewein Biotechnologie
      • Johnson & Johnson Consumer Companies
      • Johnson & Johnson Innovation
      • Johns Hopkins University
      • JSR
      • J Craig Venter Institute
      • Kaleido Biosciences
      • Kantonsspital St. Gallen
      • Karolinska Institute
      • Keio Gijuku University
      • Kenneth Rainin Foundation (KRF)
      • Kindstar Globalgene Technology
      • King's College Hospital
      • Kings College London
      • L'Oreal
      • Latham BioPharm Group
      • Lawrence Livermore National Laboratory
      • Leiden University
      • Leidos
      • Les Laboratoires Servier
      • LNC
      • Locus Biosciences
      • Loop Genomics
      • Loreal
      • Lupus Research Alliance
      • MaaT Pharma
      • Macrogen
      • Marrone Bio Innovations
      • Mars Petcare
      • Maruho
      • Massachusetts General Hospital
      • Massachusetts Institute of Technology
      • Mawi DNA Technologies
      • Mayo Clinic
      • MD Anderson Cancer Center
      • Medical College of Wisconsin
      • Medical University of Graz
      • Memorial Sloan Kettering Cancer Center
      • Merck KGaA
      • Metabiomics
      • MetaboGen
      • Metabolon
      • Metagenics
      • Metanome
      • Micreos
      • Microba Life Sciences
      • Microbiome Insights
      • MicroBiome Therapeutics
      • Microbiome Therapeutics Innovation Group
      • Microbiotica
      • Microsoft
      • Microviable Therapeutics
      • MilliporeSigma
      • MiNiSV
      • Monsanto
      • MRM Health
      • MSD
      • MyBiotics Pharma
      • National Institutes of Health
      • National Institute of Allergy and Infectious Diseases
      • National Institute of Arthritis and Musculoskeletal Diseases
      • National Institute of Diabetes and Digestive and Kidney Diseases
      • National Psoriasis Foundation
      • National Science Foundation
      • Nestle Health Science
      • Norgen Biotek
      • Northeastern University
      • North Zealand University Hospital
      • Norwegian University of Science
      • Novome Biotechnologies
      • NuBiyota
      • Nutricion
      • Nutrilinea
      • NYU Langone Medical Center
      • Oklahoma Medical Research Foundation
      • Oncodesign
      • One Codex
      • OpenBiome
      • OpGen
      • OptiBiotix
      • Origin Biosciences
      • Osel
      • OSEO
      • Owlstone Medical
      • PanTheryx
      • Pathogenica
      • Penn State Microbiome Center
      • Persephone Biosciences
      • Pfizer
      • Pharmabiota
      • Pharmatest Services
      • Pierre Fabre
      • Plan France Relance
      • Precision Biomonitoring
      • Prescient Medical
      • Psomagen
      • PureTech Health
      • Qiagen
      • Quadram Institute
      • Quark Venture
      • Quimica Europea
      • Rebiotix
      • Research Council of Norway
      • Ritter Pharmaceuticals
      • Roswell Park Cancer Institute
      • Ruggles Family Foundation
      • Rutgers University
      • SACCO
      • Salix Pharmaceuticals
      • Sanofi
      • SATT Lutech
      • Second Genome
      • Seres Therapeutics
      • Servatus Biopharmaceuticals
      • Seven Bridges Genomics
      • Sheba Medical Center
      • Siolta Therapeutics
      • Sirenas
      • Skive Hospital
      • SkyePharma
      • Solarea Bio
      • Stanford Cancer Institute
      • Stanford University School of Medicine
      • Statens Serum Institute
      • Sun Genomics
      • Swiss Integrative Center for Human Health
      • Symbiotix Biotherapies
      • Synergie Lyon Cancer
      • Synlogic
      • Synthetic Biologics
      • Taconic Biosciences
      • Takeda Pharmaceutical
      • Tata Chemicals
      • Texas Children's Hospital
      • Thermo Fisher Scientific
      • The BioCollective
      • The Healthy Aging Company
      • The Innovation Fund
      • The Parker Institute For Cancer Immunotherapy
      • The Regents of the University of California
      • Toulouse University Hospital
      • Transgene
      • Transnetyx
      • Tsinghua University
      • UBiome
      • UCB
      • Unilever
      • UNION Therapeutics
      • Universite catholique de Louvain
      • University College Cork
      • University College Hospital, Ibadan
      • University Medical Center Utrecht
      • University of Adelaide
      • University of Alberta
      • University of British Columbia
      • University of Buffalo
      • University of California, San Diego
      • University of California, San Diego (UCSD) School of Medicine
      • University of California Irvine
      • University of Cambridge
      • University of Cape Town
      • University of Chicago
      • University of Cincinnati
      • University of Colorado
      • University of Heidelberg
      • University of Houston
      • University of Illinois
      • University of Maryland
      • University of Maryland Institute for Genome Sciences (IGS)
      • University of Maryland School of Medicine
      • University of Maryland Ventures
      • University of Michigan
      • University of Nebraska
      • University of Oslo
      • University of Pennsylvania
      • University of Rhode Island
      • University of South Alabama (USA) Mitchell Cancer Institute
      • University of Texas
      • University of Verona
      • University of Washington
      • University Paris Diderot
      • University Pierre Marie Curie
      • Valbiotis
      • Vanderbilt University
      • Vedanta Biosciences
      • Venture Life
      • Vertex Pharmaceuticals
      • Viome
      • Virginia Catalyst
      • Virginia Commonwealth University
      • Washington University in St Louis
      • Weizmann Institute
      • Wellcome Trust
      • Western Connecticut Health Network
      • Xbiome
      • Xycrobe Therapeutics
      • Yeda Research and Development Company
      • Yili Industrial Group
      • Zymo Research
    • Microbiome deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
      • Formulation
    • Microbiome deals by deal type
      • Asset purchase
      • Co-development
      • Collaborative R&D
      • Co-market
      • Contract service
      • Co-promotion
      • Cross-licensing
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Litigation
      • Manufacturing
      • Marketing
      • Option
      • Research
      • Sub-license
      • Supply
      • Termination
    • Microbiome deals by therapy area
      • Cardiovascular
      • Hypercholesterolemia
      • Hypertension
      • Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease)
      • Multiple sclerosis
      • Parkinson's disease
      • Dental
      • Dermatology
      • Acne
      • Cosmetics
      • Dermatitis
      • Diabetic foot ulcer
      • Eczema
      • Psoriasis
      • Wound healing
      • Gastrointestinal
      • Celiac disease
      • Esophagitis
      • Inflammatory bowel disease
      • Crohn's disease
      • Ulcerative colitis
      • Irritable bowel syndrome
      • Symptoms
      • Constipation
      • Diarrhea
      • General health
      • Wellness
      • Genetic disorders
      • Sickle cell disease
      • Genitourinary
      • Gynaecology
      • Endometriosis
      • Infertility
      • Vaginitis
      • Neutropenia
      • Transplantation
      • Immunology
      • AIDS
      • Allergy
      • Graft versus host disease
      • Inflammation
      • Systemic lupus erythematosus
      • Infectives
      • Bacterial
      • Clostridium difficile
      • Helicobacter Pylori
      • Tropical
      • Malaria
      • Viral
      • HIV
      • Metabolic
      • Diabetes
      • Type 2
      • Liver disease
      • Nonalcoholic steatohepatitis (NASH)
      • Metabolic syndrome
      • Nutrition and vitamins
      • Fibrosis
      • Pregnancy
      • Preterm labour
      • Oncology
      • Bile duct cancer
      • Glioblastoma
      • Cervical cancer
      • Colorectal cancer
      • Head and neck cancer
      • Lung cancer
      • Melanoma
      • Bone metastases
      • Ovarian cancer
      • Pancreatic cancer
      • Symptoms
      • Orphan disease
      • Pediatrics
      • Sleep disorders
      • Obesity
      • Respiratory
      • Asthma
      • Chronic obstructive pulmonary disease
      • Pneumonia
      • Wheeze
    • Deal type definitions
    • Further reading on dealmaking
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings